On October 25, Hyperliquid's whale positions totaled $8.122 billion, with short positions exceeding long ones, accounting for 53.44% of the total exposure. Shorts amounted to $4.341 billion, while longs were $3.781 billion, resulting in a long-to-short ratio of 0.87. Long positions collectively showed a profit of $94.15 million, whereas short positions had a combined loss of $40.15 million. Notably, one wallet held a 5x cross-margin short on Ether (ETH) at $2,322.74, showing an unrealized loss of $2.43 million. This data highlights the current bearish tilt among large investors on the platform despite some profitable long positions.
Hyperliquid whales hold $8.12 billion with shorts at 53.44%, providing context on large investor positioning. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 25, 2026 14:21 WIB: out of 50 major cryptocurrencies, 5 rose and 42 fell. Notable movers include ZIL at Rp36 with a 4.38% decrease and 56% buy order activity, ENJ at Rp449 down 4.19% with 100% sell orders, and COTI at Rp192 down 4.16% with 92% buy orders.
Bitcoin's price has remained stable within a range of $80,000 to $86,000 for nine consecutive days, with its 30-day price volatility decreasing from 13% to 6%. The key resistance level is $86,000, while support is found near the 365-day simple moving...
Hyperliquid revised its testnet operation-priority rules based on user feedback, exempting seven operation types from lowering the priority of other operations before submission finishes. The exempted operations include noop and scheduleCancel, which...
DZ BANK has integrated Cardano (ADA) into its meinKrypto platform, which already supports Bitcoin (BTC), Ether (ETH), and Litecoin (LTC). This platform combines cryptocurrency trading and custody services and is accessible through the VR Banking App ...
A major crypto market deleveraging saw over 118,000 traders liquidated, with $815-$821 million wiped from leveraged positions, mainly longs. Bitcoin fell below $80,000 and Ether approached $2,350, signaling a market correction and reduced confidence ...
BioNTech and Bristol Myers Squibb reported promising Phase 2 results for pumitamig combined with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who progressed after immunotherapy plus chemotherapy. The treatment showed a confirmed ...
